FDAnews Drug Daily Bulletin
Pharmaceuticals / Submissions and Approvals

FDA Approves Recurrence Indication for Pfizer Kidney Cancer Drug

Nov. 22, 2017
A A

The FDA added adjuvant therapy to prevent recurrence to the indications for Pfizer’s kidney cancer drug Sutent (sunitinib malate).

The indication is for adults with a high risk of recurrence of their cancer after surgical removal of a diseased kidney.

Sutent was initially approved in 2006 for treatment of kidney and stomach cancer.  It was approved for pancreatic cancer treatment in 2011.

View today's stories